On Wednesday, Following Stocks were among the “Top 100 Gainers” In U.S. Stock Exchange: Energy XXI (NASDAQ:EXXI), Synergy Resources (NYSEMKT:SYRG), Petroleo Brasileiro Petrobras (NYSE:PBR), Supernus Pharmaceuticals (NASDAQ:SUPN)
Energy XXI Ltd (NASDAQ:EXXI)’s shares picked up 5.77%, and closed at $3.85. The stock volatility for the week is 8.12%, while for the month remained 9.65%. The company holds consensus target price of $4.65.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -4.11diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -63.00% and Annual EPS growth for the past 5 years is considered as 15.20%.
The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).
Energy XXI (Bermuda) Limited is engaged in the attainment, exploration, development, production, and operation of oil and natural gas properties onshore in Louisiana and Texas, and on the Gulf of Mexico. As of June 30, 2014, the company had proved reserves of 246.2 million barrels of oil equivalent. It operated or had an interest in 984 gross producing wells on 432,954 net developed acres, counting interests in 61 producing fields. Energy XXI (Bermuda) Limited was founded in 2005 and is headquartered in Houston, Texas.
Synergy Resources Corp (NYSEMKT:SYRG), raised 5.74%, and closed at $12.53. The stock has price to sale ratio of 10.21, however, price to book ratio is 3.16. With recent incline, the year-to-date (YTD) performance reflected a -0.08% decline below last year. During the past month the stocks gain 8.77%, bringing three-month performance to 0.64% and six-month performance to 2.79%. The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
Synergy Resources Corporation engages in the attainment, development, exploitation, exploration, and production of oil and natural gas properties primarily located in the Denver-Julesburg Basin in northeast Colorado. It holds interests in the Wattenberg field covering about 31,000 net developed and undeveloped acres located in Colorado; and Northern Extension area covering about 26,000 undeveloped acres. The company also has mineral assets in Yuma and Washington Counties, Colorado. Synergy Resources Corporation is headquartered in Platteville, Colorado.
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), enhanced 5.66%, and closed at $6.35. The company holds the market capitalization of $41.55B. For the last twelve months, the stock was able to keep return on equity at 8.10%, while return on assets at 3.60%, in response to its return on investment at 2.20%. Its 20-day moving average gained 12.49%, above 50-day moving average of 0.53%, below 200-day moving average of -45.20% from the latest market price of $6.35. The mean recommendation of analysts for this stock is 2.90.(where 1=Buy, 5=Sale).
Petroleo Brasileiro S.A.?Petrobras, together with its subsidiaries, engages in the exploration, exploitation, and production of oil and gas, and energy in Brazil and internationally. The company operates in four segments: Exploration and Production, Supply, Gas and Energy, and Distribution. The Exploration and Production segment engages in the exploration, development, and production of oil, liquefied natural gas, and natural gas in Brazil; and sells petroleum and bye products produced in natural gas processing plants. The Supply segment involves in the refining, logistic, transportation, and sale of oil products, petroleum, and alcohol. It also holds interests in petrochemical companies and fertilizer plants.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN), rose 5.54%, and closed at $12.76, hitting new 52-week high of $13.04. The stock has volatility for the week is 7.73%, while for the month it is 6.20%. The company has the market capitalization of $562.59M. The company holds the book value per share of 1.66, whereas cash per share is 1.69. Price to book ratio remained 7.69, while price to sale ratio is 4.61. Analysts mean recommendation for the stock is said to be 2.20 (where 1=Buy, 5=sale).
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products comprise Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has accomplished Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has accomplished Phase IIa clinical trials for the treatment of ADHD. In addition, it is developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
